{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-23-000014","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.939820+00:00","generated_at":"2026-06-08T22:29:17.271721+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Editas Medicine Q3 2023 net loss $45.0M; cash $446.4M; EDIT-301 data at ASH","bullets":["Net loss of $45.0M ($0.55/share) vs $55.7M ($0.81/share) in Q3 2022.","Collaboration revenue $5.3M vs $42K, driven by Vor Bio Cas9 license upfront payment.","Cash and securities $446.4M; expected to fund operations into Q3 2025.","EDIT-301 clinical update from RUBY (SCD) and EdiTHAL (TDT) at ASH Dec 11.","Appointed Caren Deardorf as first Chief Commercial and Strategy Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-23-000014","json":"https://secwatch.observer/filing/0001650664-23-000014.json","markdown":"https://secwatch.observer/filing/0001650664-23-000014.md","text":"https://secwatch.observer/filing/0001650664-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066423000014/0001650664-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066423000014/edit-20231103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:29:17.271721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a22c1dc4161724fc6754338ec703d19add23437a","claim":"Editas Medicine, Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $5.3 million, net income $45.0 million net loss, EPS $0.55 per share.","evidence_excerpt":"$0.55 per share, compared to net loss of $55.7 million, or $0.81 per share, for the same period in 2022. • Collaboration and other research and development revenues increased to $5.3 million for the three months ended September 30, 2023, compared to $42.0 thousand for the same period in 2022. The increase is primarily related to an upfront payment for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066423000014/0001650664-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$5.3 million"},{"label":"Net income","value":"$45.0 million net loss"},{"label":"EPS","value":"$0.55 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}